| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-07-08 |
| タイトル |
|
|
タイトル |
Serotype distribution among adults with community-acquired pneumococcal pneumonia in Japan between 2019 and 2022: A multicenter observational study |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Pneumococcal pneumonia |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
serotype distribution |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
pneumococcal conjugatevaccines |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
adult |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Japan |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
nursing home |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Maeda, Haruka
Ito, Isao
Sando, Eiichiro
Hamao, Nobuyoshi
Shirata, Masahiro
Dhoubhadel, Bhim Gopal
Ntiamoah, Desmond Opoku
Oi, Issei
Nishioka, Kensuke
Fujii, Hiroshi
Okamura, Kayoko
Inoue, Taisei
Yamada, Takashi
Niibayashi, Seisuke
Tsukino, Mitsuhiro
Fujii, Yuya
Tsuchiya, Michiko
Nakahara, Yasuharu
Hasegawa, Yoshinori
Nakagawa, Atsushi
Sugita, Takakazu
Ito, Akihiro
Sakai, Naoki
Kaji, Yusuke
Toyoda, Yuko
Urata, Tomoyuki
Asoh, Norichika
Nishiyama, Akira
Yagiuchi, Ai
Morikawa, Toru
Ushiki, Atsuhito
Ishida, Masayuki
Morimoto, Konosuke
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Streptococcus pneumoniae is a leading cause of community-acquired pneumonia (CAP) in adults. With the introduction of pneumococcal conjugate vaccines (PCVs) into pediatric national immunization programs, the serotype distribution of pneumococcal disease among adults has changed due to indirect effect. In Japan, PCV15 and PCV20 have been introduced, and PCV21 is under review for approval in adults. This multicenter observational study assessed pneumococcal serotypes in 583 adult patients with community-acquired, culture-positive pneumococcal pneumonia from May 2019 to December 2022. Pneumococcal isolates were serotyped using the Quellung reaction. The median patient age was 74 years (interquartile range: 66–82 years), 383 (65.7%) patients were male, 387 (66.4%) patients had one or more underlying medical conditions, 425 patients (72.9%) were hospitalized, and 305 (52.3%) had a CURB-65 score ≥2. The most common serotypes were serotype 3 (12.5%), 35B (12.0%), 15A (7.7%), 11A (6.7%), and 23A (6.3%). The proportion of serotypes covered by PCV13, PCV15, PCV20, PPSV23, and PCV21 were 24.0, 28.0, 43.7, 44.1, and 71.9%, respectively. The proportions of vaccine-covered serotypes were similar between patients aged <65 and ≥65 years. Serotype 3 was more prevalent among patients living in nursing homes (25.9%) compared with those living at home (11.2%). The proportions of PCV20- and PCV21-covered serotypes suggest that these new vaccines may offer additional protection against adult pneumococcal pneumonia. Given the availability of newly developed PCVs for adults in Japan, reassessing the optimal pneumococcal vaccination policy for adults is warranted. |
|
言語 |
en |
| 書誌情報 |
en : Human Vaccines & Immunotherapeutics
巻 21,
号 1,
p. art. no. 2518847,
発行日 2025-06-27
|
| 出版者 |
|
|
出版者 |
Taylor & Francis Group, LLC |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
2164-5515 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1080/21645515.2025.2518847 |
| 権利 |
|
|
権利情報 |
© 2025 The Author(s). Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Human Vaccines and Immunotherapeutics, 21(1), art. no. 2518847; 2025 |
|
言語 |
en |
HVI21_2518847.pdf (4.9 MB)
